Search
Cryptenamine
go.drugbank.com/drugs/DB00785ApprovedCryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). … Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known.
Categories: Heterocyclic Compounds with 4 or More RingsTrabedersen
go.drugbank.com/drugs/DB05697InvestigationalSynonyms: DNA, D(P-THIO)(C-G-G-C-A-T-G-T-C-T-A-T-T-T-T-G-T-A)ALS-08
go.drugbank.com/drugs/DB05705ExperimentalALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
ICX-RHY
go.drugbank.com/drugs/DB05716ExperimentalICX-RHY is an investigational therapy comprised of cultured allogeneic fibroblasts.
PMI-001
go.drugbank.com/drugs/DB05730ExperimentalIt is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis … PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.
Cefilavancin
go.drugbank.com/drugs/DB05735InvestigationalCefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that exhibits substantially greater activity than its component parts against Gram-positive bacteria.
Categories: Heterocyclic Compounds, 2-RingAGS-005
go.drugbank.com/drugs/DB05741ExperimentalAGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's
AGS-004
go.drugbank.com/drugs/DB05742InvestigationalAGS-004 is a personalized RNA-loaded dendritic cellbased immunotherapy that is designed to stimulate the patient’s immune system to target and destroy the patient’s own unique viral burden. … A personalized immunotherapy addresses these issues because it is able to capture private viral mutations, providing a matched, complete immune response for each individual HIV patient.
PF-03187207
go.drugbank.com/drugs/DB05746InvestigationalPF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. … Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP.